Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major worldwide health problem. Recent studies suggest that the gut microbiota influences NAFLD pathogenesis. Here, a murine model of high-fat diet-induced (HFD-induced) NAFLD was used, and the effects of alterations in the gut microbiota on NAFLD were determined. Mice treated with antibiotics or tempol exhibited altered bile acid composition, with a notable increase in conjugated bile acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling. Compared with control mice, animals with intestine-specific Fxr disruption had reduced hepatic triglyceride accumulation in response to a HFD. The decrease in hepatic triglyceride accumulation was mainly due to fewer circulating ceramides, which was in part the result of lower expression of ceramide synthesis genes. The reduction of ceramide levels in the ileum and serum in tempol- or antibiotic-treated mice fed a HFD resulted in downregulation of hepatic SREBP1C and decreased de novo lipogenesis. Administration of C16:0 ceramide to antibiotic-treated mice fed a HFD reversed hepatic steatosis. These studies demonstrate that inhibition of an intestinal FXR/ceramide axis mediates gut microbiota-associated NAFLD development, linking the microbiome, nuclear receptor signaling, and NAFLD. This work suggests that inhibition of intestinal FXR is a potential therapeutic target for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hence, treatment with antibiotics ameliorates high-fat-diet-induced NAFLD in mice55.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [55]
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“FXR, the central sensor and regulator for the biosynthesis and enterohepatic recycling of bile acids, plays a pivotal role in the control of lipid metabolism (42–45).”
Self-citation
Research works printed but not linked: 1
- 10.1172/jci21025 · DOI · Paper page
Cited by
Items 401–500 of 746
Dong, Y.-Q., Zhang, X.-Z., Sun, L., Zhang, S., Liu, B., Liu, H., Wang, X., & Jiang, C. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.127 · Cited by 27
Self-citationClock Genes, Metabolism, and Cardiovascular Risk
Tarquini, R., & Mazzoccoli, G. (2017) · Heart Failure Clinics · doi:10.1016/j.hfc.2017.05.001 · Cited by 27
Steroid Hormone Receptors and Signal Transduction Processes
Klinge, C. M. (2018) · Endocrinology · doi:10.1007/978-3-319-44675-2_9 · Cited by 26
Structural basis of tropifexor as a potent and selective agonist of farnesoid X receptor
Jiang, L., Xiao, D., Li, Y., Dai, S., Qu, L., Chen, X., Guo, M., Wei, H., & Chen, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.10.039 · Cited by 26
Moreau, F., Brandão, B. B., Liu, X., Tremblay, F., Fitzgerald, K. J., Ávila-Pacheco, J., Clish, C. B., Kahn, R., & Softic, S. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100324 · Cited by 26
Biomolecular Actions by Intestinal Endotoxemia in Metabolic Syndrome
Charitos, I. A., Aliani, M., Tondo, P., Venneri, M. G., Castellana, G., Scioscia, G., Castellaneta, F., Lacedonia, D., & Carone, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052841 · Cited by 26
Gil‐Gómez, A., Brescia, P., Rescigno, M., & Romero‐Gómez, M. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723752 · Cited by 26
Bile acid dysmetabolism in the gut‐microbiota‐liver axis under hepatitis C virus infection
Inoue, T., Funatsu, Y., Ohnishi, M., Isogawa, M., Kawashima, K., Tanaka, M., Moriya, K., Kawaratani, H., Momoda, R., Iio, E., et al. (2021) · Liver International · doi:10.1111/liv.15041 · Cited by 26
Senavirathna, T., Shafaei, A., Lareu, R. R., & Balmer, L. A. (2024) · Antioxidants · doi:10.3390/antiox13040485 · Cited by 25
Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders
Wang, B., Wang, L., Wang, H., Dai, H., Lu, X., Lee, Y. K., Gu, Z., Zhao, J., Zhang, H., Chen, W., et al. (2021) · Journal of Nutrition · doi:10.1093/jn/nxab103 · Cited by 25
Liu, H., Sun, Y., Nie, C., Xie, X., Yuan, X., Ma, Q., Zhang, M., Chen, Z., Hu, X., & Li, J. (2022) · Food & Function · doi:10.1039/d2fo01167k · Cited by 25
SOD1 deficiency alters gastrointestinal microbiota and metabolites in mice
Haruka, S., Shibuya, S., Kato, T., Nakanishi, Y., Tsuboi, A., Moriya, S., Ohno, H., Miyamoto, H., Kodama, H., & Shimizu, T. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110795 · Cited by 25
Characterization and comparison of lipids from human and ewe colostrum based on lipidomics analysis
Wang, S., Liu, Z., Song, Y., Zhang, Y., Zhao, L., Zhang, L., Lü, X., Wang, H., Zhang, X., Zhang, J., et al. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2022.133998 · Cited by 25
Self-citationTsuji, Y., Kaji, K., Kitade, M., Kaya, D., Kitagawa, K., Ozutsumi, T., Fujinaga, Y., Takaya, H., Kawaratani, H., Namisaki, T., et al. (2020) · Microorganisms · doi:10.3390/microorganisms8060925 · Cited by 25
Zhang, N., Liu, J., Chen, Z., Chen, N., Gu, F., & He, Q. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.832915 · Cited by 24
Takahashi, S., Tanaka, N., Golla, S., Fukami, T., Krausz, K. W., Polunas, M., Weig, B., Masuo, Y., Xie, C., Jiang, C., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx094 · Cited by 24
Self-citationInvolvement of Gut Microbial Metabolites Derived from Diet on Host Energy Homeostasis
Nishida, A., Ando, Y., Kimura, I., & Miyamoto, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105562 · Cited by 24
Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review)
Ma, Q., Liu, K., Chang, C., Wang, L., Shen, Z.-Y., Li, J., Adu, M., Lin, Q., Huang, H., Wu, X., et al. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5668 · Cited by 23
Tong, Q., Gao, X., Lei, L., Feng, J., Zhang, W., Hu, Y., Shen, Z., Liu, Z., Huan, Y., Wu, S., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115307 · Cited by 23
Self-citationSeal, A., Hughes, M., Wei, F., Pugazhendhi, A. S., Ngo, C., Ruiz, J., Schwartzman, J. D., & Coathup, M. J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053024 · Cited by 23
Gut microbiota in non-alcoholic fatty liver disease: Pathophysiology, diagnosis, and therapeutics
Pandey, H., Goel, P., Srinivasan, V. M., Tang, D. W. T., Wong, S. H., & Lal, D. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i6.106849 · Cited by 23
Emerging role of carboxylesterases in nonalcoholic fatty liver disease
Liu, J., Yao, B., Gao, L., Zhang, Y., Huang, S., & Wang, X. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115250 · Cited by 22
Chi, L., YifeiYang, Bian, X., Gao, B., Tu, P., Ru, H., & Lü, K. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.169603 · Cited by 22
Wang, L. J., Sun, J., Chen, S., Sun, Y., Zheng, Y., & Feng, J. C. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2024.1490929 · Cited by 22
Bariatric surgery, lipoprotein metabolism and cardiovascular risk
Tailleux, A., Rouskas, K., Pattou, F. N., & Staels, B. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000197 · Cited by 22
Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?
Dong, T. S., & Jacobs, J. P. (2019) · Experimental Biology and Medicine · doi:10.1177/1535370219836739 · Cited by 22
Liu, Q., Zhang, L., Allman, E. L., Hubbard, T. D., Murray, I. A., Hao, F., Tian, Y., Gui, W., Nichols, R. G., Smith, P. B. W., et al. (2021) · Toxicology · doi:10.1016/j.tox.2021.152831 · Cited by 22
Self-citationThe Impact of Phytochemicals in Obesity-Related Metabolic Diseases: Focus on Ceramide Metabolism
Kim, E., & Jeon, S. (2023) · Nutrients · doi:10.3390/nu15030703 · Cited by 22
Lee, K., & Jayaraman, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.013 · Cited by 22
Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma
Xie, Y., Sun, R.-Z., Gao, L., Guan, J., Wang, J.-Y., Bell, A. W., Zhu, J., Zhang, M., Xu, M.-S., Lu, P., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1880 · Cited by 18
Xia, Y., Xu, Y., Liu, Q., Zhang, J., Zhang, Z., Jia, Q., Tang, Q., Jing, X., Li, J., Chen, J.-H., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155610 · Cited by 21
Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
Shao, Y., Chen, S., Liu, H., & Liu, J. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00748-x · Cited by 21
Zhang, X., Chang, K., Yu, J. Q., & Loomba, R. S. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-111523-023430 · Cited by 21
Gut Microbiota and Heart, Vascular Injury
Zeng, C., & Tan, H. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2385-4_8 · Cited by 21
Myronovych, A., Bhattacharjee, J., Salazar-Gonzalez, R.-M., Tan, B. K., Mowery, S., Ferguson, D. L., Ryan, K. K., Zhang, W., Zhao, X., Oehrle, M., et al. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00175.2020 · Cited by 21
Banini, B. A., & Sanyal, A. J. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2020.11.001 · Cited by 21
Marchianò, S., Biagioli, M., Roselli, R., Zampella, A., Giorgio, C. D., Bordoni, M., Bellini, R., Morretta, E., Monti, M. C., Distrutti, E., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202101397r · Cited by 22
Lifestyle alters GUT-bacteria function: Linking immune response and host
Jazayeri, O., Daghighi, S. M., & Rezaee, F. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.009 · Cited by 21
Microbiota-Immune Interactions Regulate Metabolic Disease
Klag, K. A., & Round, J. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100419 · Cited by 20
Guo, G.-J., Yao, F., Lu, W.-P., & Xu, H. (2023) · World Journal of Hepatology · doi:10.4254/wjh.v15.i7.867 · Cited by 20
Xu, P., Xi, Y., Kim, J., Zhu, J., Zhang, M., Xu, M., Ren, S., Yang, D., Ma, X., & Xie, W. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.006 · Cited by 20
Tzeng, H., & Lee, W. (2024) · Nutrients · doi:10.3390/nu16091388 · Cited by 20
Vesković, M. N., Pejović, M., Šutulović, N., Hrnčić, D., Rašić-Marković, A., Stanojlović, O. P., & Mladenović, D. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137405 · Cited by 20
High-fat feeding drives the intestinal production and assembly of C 16:0 ceramides in chylomicrons
Mah, M., Cao, E., Anderson, D., Escott, A. B. J., Tegegne, S., Gracia, G., Schmitz, J., Brodesser, S., Zaph, C., Creek, D. J., et al. (2024) · Science Advances · doi:10.1126/sciadv.adp2254 · Cited by 20
Chen, J., Yang, H., Qin, Y., Zhou, X., & Ma, Q. (2024) · Research · doi:10.34133/research.0515 · Cited by 20
Zhou, H., Huang, Y., Chen, C., Song, M., & Hylemon, P. B. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100120 · Cited by 19
The Role of Gut Microbiota in Host Lipid Metabolism: An Eye on Causation and Connection
Wang, K., Liang, X., Pang, Y., & Jiang, C. (2019) · Small Methods · doi:10.1002/smtd.201900604 · Cited by 19
Self-citationPhytosterols as bioactive food components against nonalcoholic fatty liver disease
Yang, J., & Ji, H. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.2006137 · Cited by 19
New drug therapies for metabolic dysfunction-associated steatohepatitis
Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 19
The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice
Qiu, Y., Shen, L., Fu, L., Yang, J., Cui, C., Li, T., Li, X., Fu, C., Gao, X., Wang, W., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05095-7 · Cited by 19
NASH and the Gut Microbiome: Implications for New Therapies
Tsay, C. J., & Lim, J. K. (2022) · Clinical Liver Disease · doi:10.1002/cld.1170 · Cited by 20
Bellucci, E., Chiereghin, F., Pacifici, F., Donadel, G., Stefano, A. D., Malatesta, G., Valente, M. G., Guadagni, F., Infante, M., Rovella, V., et al. (2023) · PubMed · doi:10.26355/eurrev_202303_31558 · Cited by 19
Lallement, J., Raho, I., Merlen, G., Rainteau, D. P., Croyal, M., Schiffano, M., Kassis, N., Doignon, I., Soty, M., Lachkar, F., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2023.159333 · Cited by 19
Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis
Li, Z., Kong, C., Mao, Y., Chen, H., Zhang, S., Huang, J., Yao, J.-Q., Cai, P., Xie, N., Han, B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106902 · Cited by 18
Chen, C., Zhang, B., Tu, J., Peng, Y., Zhou, Y., Yang, X., Yu, Q.-M., & Tan, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115992 · Cited by 18
Felicianna, Lo, E. K. K., Chen, C., Ismaiah, M. J., Zhang, F., Leung, H. K. M., & El-Nezami, H. S. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.109885 · Cited by 18
Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation
Lu, D., Liu, Y., Luo, Y., Zhao, J., Feng, C., Xue, L., Xu, J., Wang, Q., Yan, T., Xiao, P., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159089 · Cited by 18
Self-citationGanesan, R., Gupta, H., Jeong, J., Sharma, S. P., Won, S., Oh, K., Yoon, S. J., Kim, D. J., & Suk, K. T. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121626 · Cited by 18
Yang, C., Xu, Z., Huang, Q., Wang, X., Huang, F., & Deng, Q. (2023) · Food Science and Human Wellness · doi:10.1016/j.fshw.2023.03.036 · Cited by 17
Zhang, N., Wu, Y., Zhong, W., Xia, G., Xia, H., Wang, L., Wei, X.-H., Li, Y., Shang, H., He, H., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154148 · Cited by 17
Pereira-Fantini, P. M., Lapthorne, S., Gahan, C. G. M., Joyce, S. A., Charles, J., Fuller, P. J., & Bines, J. E. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.02.008 · Cited by 17
Role of gut microbiota in the development of non-alcoholic fatty liver disease
Wang, X., Xia, J., & Jiang, C. (2019) · Liver Research · doi:10.1016/j.livres.2019.01.006 · Cited by 18
Self-citationEmerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yang, Y., Zhao, Y., Li, W., Wu, Y., Wang, X., Wang, Y., Liu, T.-M., Ye, T., Xie, Y., Cheng, Z., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112311 · Cited by 17
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 17
Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease
Maher, S., Rajapakse, J., El-Omar, E. M., & Zekry, A. (2024) · Seminars in Liver Disease · doi:10.1055/a-2438-4383 · Cited by 16
Ceramide dependent lipotoxicity in metabolic diseases
Li, Y., Tippetts, T. S., & Chaurasia, B. (2017) · Nutrition and Healthy Aging · doi:10.3233/nha-170032 · Cited by 17
Yang, Q., Zhang, L., Li, Q., Gu, M., Qu, Q., Yang, X., Yi, Q., Gu, K., Kuang, L., Hao, M., et al. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02526-w · Cited by 16
Self-citationXu, J., Yao, X., Li, X., Xie, S., Chi, S., Zhang, S., Cao, J., & Tan, B. (2022) · Fish Physiology and Biochemistry · doi:10.1007/s10695-022-01130-z · Cited by 16
Kasai, K., Igarashi, N., Tada, Y., Kani, K., Takano, S., Yanagibashi, T., Usui‐Kawanishi, F., Fujisaka, S., Watanabe, S., Ichimura‐Shimizu, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044050 · Cited by 16
Popov, J., Despot, T., Rodriguez, D. A., Khan, I. I., Mech, E., Khan, M. A., Bojadzija, M., & Pai, N. (2024) · Nutrients · doi:10.3390/nu16111668 · Cited by 16
Bile Acid-Induced Liver Injury in Cholestasis
Li, T., & Chiang, J. Y. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-53774-0_7 · Cited by 16
Tryptophan-induced pathogenesis of breast cancer
Cao, Z., Qin, X., Liu, F., & Zhou, L. (2015) · African Health Sciences · doi:10.4314/ahs.v15i3.36 · Cited by 16
Therapeutic manipulation of the microbiome in liver disease
Parthasarathy, G., Malhi, H., & Bajaj, J. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000987 · Cited by 15
López-Pascual, A., Russo-Cabrera, J. S., Ardaiz, N., Palmer, T., Graham, A.-R., Uriarte, I., Gomar, C., Ruiz-Guillamon, D., Latasa, M. U., Arechederra, M., et al. (2024) · Clinical Science · doi:10.1042/cs20241137 · Cited by 15
A critical role for Phocaeicola vulgatus in negatively impacting metformin response in diabetes
Chen, M., Peng, Y., Hu, Y., Kang, Z., Chen, T., Zhang, Y., Chen, X., Li, Q., Yuan, Z., Wu, Y., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.02.008 · Cited by 15
Disentangling Organ‐Specific Roles of Farnesoid X Receptor in Bile Acid and Glucolipid Metabolism
Li, T., Fu, C., Tang, Z., Li, C., Hua, D., Liu, B., Tao, Z., Yang, J., Zhang, L., Cheng, T., et al. (2025) · Liver International · doi:10.1111/liv.70027 · Cited by 15
Self-citationLiu, Y., Tan, Y., Huang, J., Wu, C., Fan, X., Stalin, A., Lu, S., Wang, H., Zhang, J., Zhang, F., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.875700 · Cited by 16
Intestinal microbiota-farnesoid X receptor axis in metabolic diseases
Zou, B., Yang, W., Tang, Y., Hou, Y., Tang, T., & Qu, S.-L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.006 · Cited by 15
Qi, Z., Song, N., Wang, S.-Q., Wang, Y., Zhao, Y.-K., & Zhu, X.-D. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9922292 · Cited by 15
Liver steatosis induced by small bowel resection is prevented by oral vancomycin
Barron, L. M., Gayer, C. P., Roberts, A. S., Golden, J. M., Aladegbami, B. G., Guo, J., Erwin, C. R., & Warner, B. W. (2016) · Surgery · doi:10.1016/j.surg.2016.07.018 · Cited by 15
Li, L., Yang, S., Liang, X., Liu, Y., Xu, H., Guo, X., Xie, C., & Xu, X. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250218 · Cited by 14
Self-citationHe, F., Du, W., Liu, Y., Ling, Y., Xu, M. J., Liu, J., Song, P., Fang, Z., Yue, Z., Duan, J., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103488 · Cited by 14
Self-citationHost–Microbiome Interaction in the Intensive Care Unit
Neag, M. A., Mitre, A. O., Pomana, I. G., Velescu, M. A., Militaru, C. F., Nagy, G. A., & Melincovici, C. S. (2025) · Diseases · doi:10.3390/diseases13080250 · Cited by 14
Acidic Activated Charcoal Prevents Obesity and Insulin Resistance in High-Fat Diet-Fed Mice
Zhang, X., Diao, P., Yokoyama, H., Inoue, Y., Tanabe, K., Wang, X., Hayashi, C., Yokoyama, T., Zhang, Z., Hu, X., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.852767 · Cited by 14
Self-citationChen, C., Liu, L., Zhong, Y., Wang, M., Ai, Y., Hou, Y., Chen, H., Lin, X., Zhang, Y., Ding, M., et al. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109358 · Cited by 14
Patented Farnesoid X receptor modulators: a review (2019 – present)
Gioiello, A., Rosatelli, E., & Cerra, B. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2314296 · Cited by 14
Farnesoid X receptor (FXR) as a potential therapeutic target for lung diseases: a narrative review
Cao, Y., Xu, Y., Zhou, J., Fu, X., Zhang, H., Du, X., Liang, S., & Liu, M. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-734 · Cited by 13
Luo, X., Huang, W., Lu, C.-H., Wu, G., Feng, Z.-X., Shen, S., Chen, M.-Z., Zheng, S.-S., & Yang, Z. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1638372 · Cited by 13
Li, J., Zhang, H., Dong, Y., Wang, X., & Wang, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.628122 · Cited by 13
Bioactive lipids and metabolic syndrome—a symposium report
DeVito, L. M., Dennis, E. A., Kahn, B. B., Shulman, G. I., Witztum, J. L., Sadhu, S., Nickels, J. T., Spite, M. R., Smyth, S. S., & Spiegel, S. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14752 · Cited by 13
Resilience and the Gut Microbiome: Insights from Chronically Socially Stressed Wild-Type Mice
Guilherme, M. D. S., Valeri, F., Winter, J., Müller, M. B., Schwiertz, A., & Endres, K. (2022) · Microorganisms · doi:10.3390/microorganisms10061077 · Cited by 13
Jiang, N., Xiao, Y., Yuan, K., & Wang, Z. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16129 · Cited by 13
Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
Xiang, M., Xu, Q., Han, L., Wang, H., Wang, J., Liu, W., Gu, Y., Yao, S., Yang, J., Zhang, Y., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106561 · Cited by 13
Chronic corticosterone exposure disrupts hepatic and intestinal bile acid metabolism in chicken
Wu, L., Liu, X., Zhang, A., Chen, H., Zhao, R., & Jia, Y. (2023) · Frontiers in Veterinary Science · doi:10.3389/fvets.2023.1147024 · Cited by 13
Potential role of bile acids in the pathogenesis of necrotizing enterocolitis
Yang, J., Chen, X., Liu, T., & Shi, Y. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122279 · Cited by 13
Teno, N., Yamashita, Y., Masuda, A., Iguchi, Y., Oda, K., Fujimori, K., Hiramoto, T., Nishimaki‐Mogami, T., Une, M., & Gohda, K. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.029 · Cited by 13
The Physiological Importance of Bile Acid Structure and Composition on Glucose Homeostasis
Higuchi, S. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01329-5 · Cited by 13
RNA-Seq transcriptome analysis of ileum in Taiping chicken supplemented with the dietary probiotic
Luo, L., Wang, Q., & Ma, F. (2021) · Tropical Animal Health and Production · doi:10.1007/s11250-021-02566-w · Cited by 13
Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease
Ахмедов, В. А., & Gaus, O. V. (2019) · Terapevticheskii arkhiv · doi:10.26442/00403660.2019.02.000051 · Cited by 13
Joon, A., Sharma, A., Jalandra, R., Bayal, N., Dhar, R., & Karmakar, S. (2024) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00018 · Cited by 12
Metadata
- Authors
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 386-402
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4382255
- OpenAlex
- W2124025733
- Cited by
- 693
- References
- 68
- Citations by year
- 2026: 43 · 2025: 52 · 2024: 52 · 2023: 61 · 2022: 76 · 2021: 84 · 2020: 70 · 2019: 63 · 2018: 58 · 2017: 61 · 2016: 46 · 2015: 26
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- non-alcoholic fatty liver disease, gut microbiota, bile acids, bile acid conjugates, ceramide, ceramide synthesis, SREBP-1c, de novo lipogenesis, hepatic steatosis, high-fat diet, antibiotic therapy, tempol, nuclear receptor signaling, therapeutic target
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cecum, Gene Expression Regulation, Humans, Ileum, Liver, Male, Mice, Inbred C57BL, Mice, Transgenic, Gene Expression, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Metabolic Networks and Pathways, Diet, High-Fat, Mitochondrial Dynamics, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.